Prøve GULL - Gratis

Vax Cocktail Endgame Against Covid-19

BioSpectrum Asia

|

BioSpectrum Asia Sep 2021

The world has been under the deadly spell of the coronavirus, with multiple waves of the pandemic decimating lives and economy in a fell swoop. In a record short span of time, numerous vaccines were developed to combat COVID-19. However, the ground reality seems, as per some experts, that administering a mix of vaccines presents better outcomes. Whether this approach holds good, needs a closer look.

- Ayesha Siddiqui

Vax Cocktail Endgame Against Covid-19

Vaccine mixing, which began unintentionally, is now gaining traction. There is a significant interest in mixing two different types of COVID-19 vaccines to mitigate against supply shocks or shortages that might otherwise reduce the speed of vaccine roll-out.

Canada which sort of started this trend unintentionally to manage its vaccine supply issues by allowing the mixing of vaccines. On June 1, 2021, the Canadian health agency, Health Canada asked those who had taken the Pfizer shot to take Moderna’s mRNA vaccine for their second dose. This has helped Canada overcome a supply bottleneck that delayed Pfizer doses in June.

Taking it even further, on June 17, 2021, the Canadian government recommended those who received the AstraZeneca (adenoviral vector-based vaccine) as the first dose should preferably take either the Pfizer or Moderna mRNA vaccine for their second dose. This decision was taken in light of the rare clotting events reported with the AstraZeneca vaccine.

Germany also followed suit by recommending the same AstraZeneca/Pfizer combo. The country reportedly allowed this heterologous approach on efficacy grounds.

In July 2021, Thailand became one of the first in Southeast Asia to officially start mixing vaccines. The country’s National Communicable Disease Committee issued a recommendation to give AstraZeneca jabs as the second dose to individuals who had initially received China’s Sinovac (based on inactivated virus technology), to build stronger immunity against the highly contagious delta variant which has created havoc in the country.

South Korea also introduced mix-and-match inoculations, using the AstraZeneca vaccine for the first dose and Pfizer for the second.

FLERE HISTORIER FRA BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Waters launches charge detection mass spectrometry technology

US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia

The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

WHO strengthens coordination for NTD programmes and supply chain delivery

The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

All-in-one coronavirus vaccines to save millions in future pandemics

A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

NTU in Singapore introduces Master of Science course in Chinese Medicine

From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

ProSpecBio launches Activin-A recombinant protein for brain injury research

Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

PAHO publishes guide for designing AI instructions in public health

The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Prerna launches India's first MicroRNA based blood test for breast cancer screening

Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr

India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan

Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.

time to read

1 min

BioSpectrum Asia Nov 2025

Translate

Share

-
+

Change font size